Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Breast cancer, female
Stage/Subtype:  inflammatory breast cancer
Results 1-14 of 14 for your search:
Start Over
Atorvastatin Calcium in Preventing Cardiovascular Complications in Patients with Newly Diagnosed Stage I-III Breast Cancer or Lymphoma Undergoing Anthracycline-Based Chemotherapy
Phase: Phase III, Phase II
Type: Supportive care
Age: 30 to 80
Trial IDs: 98213, NCI-2013-01760, 00024197, CCCWFU 98213, WF 98213, WFU 98213, NCT01988571
Phase 1/2 Study of ThermoDox With Approved Hyperthermia in Treatment of Breast Cancer Recurrence at the Chest Wall
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 105-08-201, NCI-2010-01317, NCT00826085
Romidepsin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients with Metastatic Inflammatory Breast Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: Over 18
Trial IDs: 13P.387, NCI-2013-01695, 080-38270-J94401, 13C.387, 2013-35, NCT01938833
I-SPY 2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 097517, NCI-2015-00014, NCT01042379
Dovitinib Lactate in Treating Patients with Relapsed HER2-Negative Stage IV Inflammatory Breast Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2010-0296, NCI-2011-00299, NCT01262027
Accelerated Radiation Therapy after Surgery in Treating Patients with Breast Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 041001, NCI-2011-01124, NCT01417286
Ruxolitinib Phosphate in Treating Patients With Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed By Surgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-024, NCI-2012-00992, NCT01562873
Paclitaxel, Trastuzumab, and Pertuzumab before Surgery in Treating Patients with Inflammatory Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-497, NCI-2013-01110, ML28193, NCT01796197
Nintedanib in Treating Patients with Metastatic HER2-Negative Inflammatory Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2014-0464, NCI-2015-00506, NCT02389764
Pembrolizumab in Treating Patients with Stage IV Metastatic or Recurrent Inflammatory Breast Cancer Who Have Received Prior Chemotherapy with Clinical Response
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2014-0533, NCI-2015-00671, NCT02411656
Dose-escalation Study of Oral CX-4945
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: C4-08-001, NCI-2009-01571, NCT00891280
Zirconium Zr 89 Bevacizumab Positron Emission Tomography in Imaging Tumor Angiogenesis in Patients with Inflammatory Breast Cancer Receiving Preoperative Chemotherapy
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Diagnostic
Age: 21 and over
Trial IDs: 13-147, NCI-2015-01107, NCT01894451
Tc 99m Sestamibi Molecular Breast Imaging in Predicting Tumor Response in Patients with Locoregional Invasive Breast Cancer Receiving Neoadjuvant Chemotherapy
Phase: No phase specified
Type: Diagnostic
Age: 18 and over
Trial IDs: 2014-0812, NCI-2015-00035, NCT02324387
Start Over